NIPH Clinical Trials Search

Basic Information

Recruitment status	recruiting
Health condition(s) or Problem(s) studied
Date of first enrollment	10/07/2020
Target sample size	870
Countries of recruitment	Asia except Japan,Japan,North America,South America,Europe
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : INN of investigational material : pembrolizumab, etoposide, carboplatin, cisplatin, paclitaxel, pemetrexed Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : pembrolizumab, olaparib, etoposide, carboplatin, cisplatin, paclitaxel, pemetrexed Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : etoposide, carboplatin, cisplatin, paclitaxel, pemetrexed, durvalumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcome	efficacy
Secondary Outcome	efficacy safety

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	<= 120age old
Gender	Both
Include criteria
Exclude criteria